Secondary analysis supports extension of treatment window for alteplase in stroke

摘要

Further evidence to support extending the treatment window for alteplase in stroke to 4.5 hours is published this week in The Lancet Neurology (21 October 2009). The drug is currently licensed for use within three hours following stroke.Researchers conducted a secondary analysis of data from the.ECASS III trial, originally published in 2008.. Findings from the trial suggested that alteplase treatment resulted in better outcomes than placebo when given in the 3.0-4.5 hour window after stroke.